All articles from EyeWorld.org on the topic of blepharitis. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.

Updates expected for the ASCRS Preoperative OSD Algorithm

Several years ago, the ASCRS Cornea Clinical Committee created the ASCRS Preoperative OSD Algorithm because of the lack of awareness and consensus regarding recommendations on ocular surface disease. The Committee is currently working on updates to the algorithm as new therapies have been introduced.

Comments Off on Updates expected for the ASCRS Preoperative OSD Algorithm

Best practices: back to basics

“Best practices are the summation of the technical aspects of medicine. They are, in effect, the perfection of the form of medicine,” said Julie Schallhorn, MD. She shared this and other thoughts on best practices and gave a preview of the articles in the Cornea section of the issue.

Comments Off on Best practices: back to basics

Blepharitis: types, presentation, and treatment

Blepharitis is commonly seen by ophthalmologists. This inflammation of the eyelid margins can be acute or chronic and has a multitude of etiologies. This article gives an in-depth look at the condition, with helpful insights from two experts.

Comments Off on Blepharitis: types, presentation, and treatment

EyeWorld Weekly, November 18, 2022

➤ FDA approves AI-based diabetic retinopathy screener ➤ FDA accepts NDA for Demodex treatment ➤ Phase 2b results for MGD therapy ➤ Phase 1/2 trial evaluates investigational TED treatment ➤ Phase 1 clinical trial to study synthetic cannabinoid derivative for glaucoma ➤ OCT company rebrands ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, November 18, 2022

EyeWorld Weekly, March 11, 2022

➤ Launch of IOL made with new ‘glistening-free’ material ➤ Enrollment complete in study of mydriasis-reversing drop in a pediatric group ➤ Acquisition of electrophysiology medical device company ➤ Licensing of investigational neuroprotective drug ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, March 11, 2022

Signs of rosacea and how to treat

Rosacea can be a significant problem for many patients and may be more prevalent than physicians think. Depending on the subtype, there may be ocular involvement. Three physicians discussed treatment strategies, in addition to sharing what to look for and how to diagnose.

Comments Off on Signs of rosacea and how to treat

EyeWorld Weekly, February 11, 2022

➤ FDA approves generic Restasis ➤ Phase 3 trial for novel, preservative-free drug delivery platform ➤ Enrollment complete for Phase 3 blepharitis trial ➤ Enrollment complete for Phase 3 mydriasis reversal study ➤ Path forward for resubmission of drug-device combination product ➤ ‘Immunity and Inflammation in the Anterior Segment of the Eye’ report ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, February 11, 2022

EyeWorld Weekly, October 8, 2021

➤ Positive topline results from Phase 3 trial for first-in-class dry eye drop ➤ Study: Long-term efficacy of neuromyelitis optica spectrum disorder treatment ➤ Long-term data from gene therapy injection for wet AMD ➤ Positive data from Phase 1/2 trial of gene therapy for geographic atrophy ➤ Ophthalmic device company partners with augmented reality tech company

Comments Off on EyeWorld Weekly, October 8, 2021

EyeWorld Weekly, October 1, 2021

➤ Survey: Patient perspectives on presbyopia ➤ Study: Wearable visual field testing device correlates with standard testing, offers efficiency ➤ Endpoints not met in blepharitis drug trial ➤ Retinal cell protection observed in non-clinical model with investigational IOP-lowering drug ➤ Extension study of investigational wet AMD therapy shows reduction of injection burden ➤ 12-month safety data reported from Phase 3 bevacizumab trial ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, October 1, 2021